Israeli scientists say a new study has shown that a small molecule called PJ34 triggered the self-destruction of human pancreatic cancer cells in mice.
According to the research, published in the peer-reviewed open-access biomedical journal Oncotarget, the administration of the molecule reduced the number of cancer cells in developed tumors by up to 90 percent in 30 days.
Sign up for our free weekly newsletterSubscribe
The study was led by Professor Malka Cohen-Armon and her team at Tel Aviv University’s Sackler Faculty of Medicine, in collaboration with Dr. Talia Golan and her team at the Cancer Research Center at Sheba Medical Center, and conducted with transplantations of human pancreatic cancer cells into immunocompromised mice, or xenografts.
“In research published in 2017, we discovered a mechanism that causes the self-destruction of human cancer cells during their duplication (mitosis) without affecting normal cells,” explained Professor Cohen-Armon in a statement by the university this week. “We have now harnessed this information to efficiently eradicate human pancreatic cancer cells in xenografts. The current results were obtained using a small molecule that evokes this self-destruction mechanism in a variety of human cancer cells.
“The mice were treated with a molecule called PJ34, which is permeable in the cell membrane but affects human cancer cells exclusively. This molecule causes an anomaly during the duplication of human cancer cells, provoking their rapid cell death. Thus, cell multiplication itself resulted in cell death in the treated cancer cells,” she added.
The study involved 24 mice divided into three groups of eight; a control group, and two treated with PJ34 at different intervals. One group of animals was administered the molecule for five consecutive days a week for three weeks, and the second group was treated with PJ34 three times a week, every second day, for three weeks.
According to the findings, only the group treated daily with PJ34 (five times a week) showed a significant reduction of about 40 percent in tumor size but both treatment regimens caused a reduction of between 80-90 percent in cancer cells a month after treatment was terminated.
In one mouse, the tumor disappeared completely on day 56 of the study.
Cohen-Armon noted that normal cells were not affected and no adverse behavioral effects were observed.
“No abnormalities, toxic signs, or animal death were observed during the study. On the contrary, all mice gained weight during the study, with no difference between control and the two PJ34 treated groups,” the study reads.
The scientists said that the “efficient eradication of malignant cells in human pancreas cancer xenografts presented a new model of pancreas cancer treatment.”
Pancreatic cancer is notoriously difficult to diagnose as often there are no symptoms in the early stages. It is also often resistant to currently available treatments and in its more advanced stages (metastatic), has a five-year-survival rate of three percent.
Professor Cohen-Armon indicated that the mechanism, tested in parallel studies, “acts efficiently” in additional types of cancer, eradicating a variety of resistant cancer cells (breast, lung, brain, and ovarian cancer) including types resistant to current therapies.
PJ34 is being tested in pre-clinical trials according to FDA regulations before clinical trials on larger animals and then humans begin, Tel Aviv University said in a statement.
Dr. Golan is a lead researcher at the Pancreas Cancer Olaparib Ongoing (POLO) Clinical Trial at the Sheba Medical Center, working specifically with patients with advanced stages of pancreatic cancer as well as a BRCA 1 or 2 germline mutation. NoCamels reported on her work this summer, which offers a promising new drug regimen.